You are here

Article Text

Article menu
Download PDFPDF
Letter
Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response
  1. F Rinaldi1,
  2. G Provenzano2,
  3. A Termini1,
  4. M Spinello1,
  5. F La Seta3
  1. 1Division of Internal Medicine II, AO “V. Cervello”, Palermo, Italy
  2. 2Department of Medicine, Division of Respiratory Diseases, Section of Systemic Autoimmune Diseases, AO “Villa Sofia-CTO”, Palermo, Italy
  3. 3Service of Radiology, AO “V. Cervello”; Palermo, Italy
  1. Correspondence to:
    Dr G Provenzano
    Department of Medicine, Division of Respiratory Diseases, Section of Systemic Autoimmune Diseases, Azienda Ospedaliera “Villa Sofia—CTO”, Via Ingegneros No 33, 90100 Palermo, Italy; giuseppe.provenzano5tin.it

https://doi.org/10.1136/ard.2004.033233

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Psoriatic arthritis (PsA) affects about 30% of patients with psoriasis and is a chronic inflammatory rheumatic disease, with the development of erosive and deforming arthritis in about 40% of patients.1 Tumour necrosis factor α (TNFα) has an established role in the pathogenesis of PsA, and the TNFα receptor blocker etanercept has been approved for its treatment.2

    There are also encouraging data about the efficacy of infliximab,3–5 but its long term efficacy and safety in PsA have been questioned.6

    METHODS AND RESULTS

    We evaluated in an open label, 2 year study the safety and efficacy of infliximab in association with methotrexate for patients with severe PsA. This study was an extension protocol of an initial 6 month study.7

    Four men and eight women with PsA and active disease despite treatment with methotrexate …

    View Full Text